On July 29, 2020, Novus International filed an antidumping petition against imports of methionine from France, Japan and Spain into the United States. Adisseo believes that these claims were unfounded, and has been working diligently to present its case to the U.S. International Trade Commission (ITC), which investigates injury to a U.S. industry, and the U.S. Department of Commerce (DOC), which determines whether unfair pricing has occurred.
While Adisseo believes that it has strong arguments before both agencies, the uncertainties generated by this proceeding has led Adisseo to make the difficult decision to discontinue any further imports of Rhodimet NP99 (DLM) from France into the U.S. market after February 2021, which is the projected date for the DOC’s preliminary determination. When there is additional clarity from the ITC and DOC regarding the final duties that may be imposed on imports from our French and Spanish production facilities, we may reevaluate this position. The final decision in this proceeding is expected in September 2021.
Adisseo would like to reassure its U.S. customers that no matter the outcome of the DOC’s decision on the antidumping case, we will continue to supply the U.S. market with its remaining product portfolio, and will meet all of its current contractual obligations. Adisseo continues to support the overall growth in the methionine sector, such as through a second production facility in Nanjing, China, which is expected to come online mid-2022. We appreciate your patience and loyalty as we work hard to refute Novus International’s claims of unfair trade.